User login
Treatment with adalimumab significantly improved quality of life and functioning among patients with moderate to severe psoriatic arthritis at 24 weeks, reported Dr. Dafna D. Gladman.
Previous analyses from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT), which is the largest randomized controlled trial of a tumor necrosis factor (TNF)-α inhibitor in psoriatic arthritis, have demonstrated that treatment with this drug significantly improves joint and skin manifestations and reduces radiographic disease progression.
But because psoriatic arthritis primarily afflicts patients in the productive years, 30–55 years, restoring function and reducing work-related disability also could help ease the economic burden of this disease, according to Dr. Gladman of the University of Toronto Rheumatic Disease Unit.
Among the 313 patients in ADEPT, those receiving adalimumab had a mean decrease of 0.4 points from a baseline score of 1.0 on the disease-specific Health Assessment Questionnaire Disability Index, which has a range of 0 to 3, while those receiving placebo had a decrease of 0.1 points, Dr. Gladman and colleagues reported (Ann. Rheum. Dis. [Epub doi: 10.1136/ard.2006.057901
By week 12, 33.8% of patients in the active treatment group had complete resolution of functional loss, compared with 14.3% of those in the placebo group, with similar results being seen at week 24, according to the investigators. Statistically significant and clinically important improvements also were seen at week 24 in seven of the eight domains of the Short Form 36 Health Survey among the adalimumab-treated patients, whereas patients receiving placebo did not experience clinically important improvements in any domain.
The investigators acknowledged that a limitation of their study was its short duration, but noted that data from the long-term, open-label extension of ADEPT are being assessed.
Treatment with adalimumab significantly improved quality of life and functioning among patients with moderate to severe psoriatic arthritis at 24 weeks, reported Dr. Dafna D. Gladman.
Previous analyses from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT), which is the largest randomized controlled trial of a tumor necrosis factor (TNF)-α inhibitor in psoriatic arthritis, have demonstrated that treatment with this drug significantly improves joint and skin manifestations and reduces radiographic disease progression.
But because psoriatic arthritis primarily afflicts patients in the productive years, 30–55 years, restoring function and reducing work-related disability also could help ease the economic burden of this disease, according to Dr. Gladman of the University of Toronto Rheumatic Disease Unit.
Among the 313 patients in ADEPT, those receiving adalimumab had a mean decrease of 0.4 points from a baseline score of 1.0 on the disease-specific Health Assessment Questionnaire Disability Index, which has a range of 0 to 3, while those receiving placebo had a decrease of 0.1 points, Dr. Gladman and colleagues reported (Ann. Rheum. Dis. [Epub doi: 10.1136/ard.2006.057901
By week 12, 33.8% of patients in the active treatment group had complete resolution of functional loss, compared with 14.3% of those in the placebo group, with similar results being seen at week 24, according to the investigators. Statistically significant and clinically important improvements also were seen at week 24 in seven of the eight domains of the Short Form 36 Health Survey among the adalimumab-treated patients, whereas patients receiving placebo did not experience clinically important improvements in any domain.
The investigators acknowledged that a limitation of their study was its short duration, but noted that data from the long-term, open-label extension of ADEPT are being assessed.
Treatment with adalimumab significantly improved quality of life and functioning among patients with moderate to severe psoriatic arthritis at 24 weeks, reported Dr. Dafna D. Gladman.
Previous analyses from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT), which is the largest randomized controlled trial of a tumor necrosis factor (TNF)-α inhibitor in psoriatic arthritis, have demonstrated that treatment with this drug significantly improves joint and skin manifestations and reduces radiographic disease progression.
But because psoriatic arthritis primarily afflicts patients in the productive years, 30–55 years, restoring function and reducing work-related disability also could help ease the economic burden of this disease, according to Dr. Gladman of the University of Toronto Rheumatic Disease Unit.
Among the 313 patients in ADEPT, those receiving adalimumab had a mean decrease of 0.4 points from a baseline score of 1.0 on the disease-specific Health Assessment Questionnaire Disability Index, which has a range of 0 to 3, while those receiving placebo had a decrease of 0.1 points, Dr. Gladman and colleagues reported (Ann. Rheum. Dis. [Epub doi: 10.1136/ard.2006.057901
By week 12, 33.8% of patients in the active treatment group had complete resolution of functional loss, compared with 14.3% of those in the placebo group, with similar results being seen at week 24, according to the investigators. Statistically significant and clinically important improvements also were seen at week 24 in seven of the eight domains of the Short Form 36 Health Survey among the adalimumab-treated patients, whereas patients receiving placebo did not experience clinically important improvements in any domain.
The investigators acknowledged that a limitation of their study was its short duration, but noted that data from the long-term, open-label extension of ADEPT are being assessed.